GABRA6
Gamma-aminobutyric acid receptor subunit alpha-6
As of the edition of 20 October 2026, GABRA6 (gamma-aminobutyric acid receptor subunit alpha-6, UniProt Q16445) has 2 drugs tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16445
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Mental health; Nervous system; Lungs and airways; Cancer; Heart and blood vessels; Hormones; Inherited and neonatal
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Zopiclone | Marketed | Phase 4 | none listed |
| Meprobamate | Marketed | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |